期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿托伐他汀治疗心力衰竭并阵发性心房颤动的研究

Atorvastatin in treatment of heart failure and paroxysmal atrial fibrillation
原文传递
导出
摘要 目的探讨阿托伐他汀治疗心力衰竭并阵发性心房颤动的临床疗效。方法选择心力衰竭并阵发性心房颤动的患者108例，随机分为治疗组（常规治疗＋阿托伐他汀组，54例）及对照组（常规治疗组，54例）。治疗并随访半年，比较治疗前后左室射血分数（LVEF）、C-反应蛋白（CRP）和脑钠肽（BNP）水平变化。结果治疗6个月后，治疗组LVEF明显高于对照组，差异有统计学意义（P〈0．05）；对照组CRP、BNP水平明显高于治疗组，差异有统计学意义（P〈0．05）。结论阿托伐他汀能改善心功能，有效降低血中CRP及BNP水平，减少心房颤动的复发。 Objective To investigate the clinical therapeutic effect of atorvastatin on patients with heart failure and paroxysmal atrial fibrillation. Methods One hundred and eight patients with heart failure and paroxysmal atrial fibrillation were divided into atorvastatin group （cony- entional therapy and atorvastatin, n = 54） and control group （ conventional therapy, n = 54） randomly. The follow-up duration for every patient was half one year. Change of the left ventricular ejection fraction, C-reactive protein （CRP） and brain natriuretic pep tide （BNP） were observed before and after treatment. Results After half one year, the left ventricular ejection fraction of atorvastatin group was significantly higher than that of control group （ P 〈 0. 05 ）. The level of CRP and BNP of control group was significantly higher than that of atorvastatin group （ P 〈 0. 05 ）. Conclusions Atorvastatin may improve the heart function and depress the level of CRP and BNP in blood and decrease the recidivation of paroxysmal atrial fibrillation.
作者 于付生 马欣 苏毅 李秋霞 付宝
机构地区 河南省焦作市第二人民医院
出处 《中国实用医刊》 2013年第1期23-24,共2页 Chinese Journal of Practical Medicine
关键词 阿托伐他汀 心力衰竭 阵发性心房颤动 Atorvastatin Heart failure Paroxysmal atrial fibrillation
分类号 R541 [医药卫生—心血管疾病]
  • 相关文献

参考文献13

  • 1Psychari SN, Apostolou TS, Srnos L,et al. Relation of elevated C-re- active protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation[ J]. Am J Cardiol, 2005, 95(6) : 764-767.
  • 2Wozakowska-Kap B. Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation[ J]. Am J Cardiol, 2004, 93 (12) : 1555-1558.
  • 3Boldt A, Wetzel U, Weigl J, et al. Expression of angiotensin II recep- tors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease [ J]. J Am Coil Cardio1,2003, 42(10) : 1785-1792.
  • 4Torres JL, Ridker PM. Clinical use of high sensitivity C-reactive pro- tein for the prediction of adverse cardiovascular events[ J]. Curr Opin Cardiol, 2003,18(6) : 471-478.
  • 5Chung MK, Martin DO, Sprecher D, et al. C-reactive protein eleva- tion in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation [ J ]. Circulation, 2001, 104 ( 24 ) : 2886-2891.
  • 6Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fi- brillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation [ J ]. Acta Cardiol, 2001, 56 (6) : 375- 380.
  • 7Sata N, Hamada N, Horinouchi T, et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrilla- tion? [J]. Jpn Heart J, 2004, 45(3) : 441-445.
  • 8Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibi- tor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model [ J ]. Cardiovasc Res, 2004,62 ( 1 ) : .1105-1111.
  • 9Shiroshita-Takeshita A, Schram G, Lavoie J, et al. Effect of simvasta- tin and antioxidant vitamins on atrial fibrillation promotion by atrial- tachyeardia remodeling in dogs [ J ]. Circulation, 2004, 110 ( 16 ) : 2313-2319.
  • 10Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion[ J ]. Am JCardio1,2003,92 ( 11 ) : 1343-1345.

二级参考文献12

  • 1Bauersachs J, Galuppo P, Fraccarollo D, et al. Circulation,2001; 104(9): 982-985.
  • 2Hayashidani S, Tsutsui H, Shiomi T, et al. Circulation,2002;105(7):868-873.
  • 3Louis AA, Manousos IR, Coletta AA, et al. Eur Heart Fail, 2002; 4(1): 111-116.
  • 4Khatta M, Alexander BS, Krichten CM, et al. Ann Intern Med, 2000; 132(8) .. 636-640.
  • 5Rauchhaus M, Coats AJ, Anker SD. Lancet, 2000; 356(9233) : 930-933.
  • 6Sacks FM, Pfeffer MA, Moye LA, et al. N Engl J Med,1996;335(14): 1001-1009.
  • 7The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998; 339(19); 1349-1357.
  • 8Kureishi Y, Luo Z, Shiojima I, et al. Nat Med, 2000; 6(9): 1004-1010.
  • 9Strehlow K, Wassmann S, Bohm M, et al. Ann Med,2000; 32(6): 386-389.
  • 10Pehlivanidis AN, Athyros VG, Demitriadis DS, et al. Atherosclerosis, 2001 - 157(2) :463-469.

共引文献12

中国实用医刊
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部